e-learning
resources
Vienna 2009
Wednesday, 16.09.2009
Biomarkers, comorbidities and prognosis of COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The natural history of COPD without co-morbidities: predictors of long-term mortality
J. M. Marin, M. Ciudad, R. Tejedor, S. J. Carrizo, B. R. Celli (Zaragoza, Spain; Boston, United States Of America)
Source:
Annual Congress 2009 - Biomarkers, comorbidities and prognosis of COPD
Session:
Biomarkers, comorbidities and prognosis of COPD
Session type:
Oral Presentation
Number:
4465
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. M. Marin, M. Ciudad, R. Tejedor, S. J. Carrizo, B. R. Celli (Zaragoza, Spain; Boston, United States Of America). The natural history of COPD without co-morbidities: predictors of long-term mortality. Eur Respir J 2009; 34: Suppl. 53, 4465
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
GURBUZ CEMAL NURI - 14.09.2009 12:37
Hb level
Hb level also is a prediktor for COPD patients morbidities.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Clinical case discussion: ERS guidelines on high flow nasal cannula in acute respiratory failure: from the clinical cases to the scientific evidence
Related content which might interest you:
Heterogeneity of the natural history and predictors of mortality
Source: Annual Congress 2013 –The future of IPF: current mysteries and challenges
Year: 2013
The effect of comorbidities on long-term survival in COPD
Source: International Congress 2018 – COPD and extrapulmonary comorbidities
Year: 2018
The impact on risk-factor analysis of different mortality outcomes in COPD patients
Source: Eur Respir J 2008; 32: 629-636
Year: 2008
Prevalence of comorbidity in patients with COPD and its effect on mortality
Source: Annual Congress 2003 - Staging and outcome in COPD
Year: 2003
COPD-related morbidity and mortality after smoking cessation: status of the evidence
Source: Eur Respir J 2008; 32: 844-853
Year: 2008
The coexistence of asthma and COPD: risk factors, clinical history and lung function trajectories
Source: Eur Respir J, 58 (5) 2004656; 10.1183/13993003.04656-2020
Year: 2021
Cardiovascular comorbidities in hospitalised COPD patients: a determinant of future risk?
Source: Eur Respir J 2015; 46: 846-849
Year: 2015
COVID-19 prevalence, risk factors and outcomes in COPD
Source: Virtual Congress 2021 – COVID-19 and obstructive diseases: risk factors, management and long-term effects
Year: 2021
Predictors of mortality in COPD
Source: Annual Congress 2009 - Prognosis and comorbidities in COPD
Year: 2009
Predictors of mortality in COPD
Source: Annual Congress 2008 - COPD - clinical and epidemiological aspects
Year: 2008
Long-term impact of COPD on postoperative cardiorespiratory morbidity and mortality: a population cohort study
Source: Virtual Congress 2021 – Patient-reported outcome measures (PROMs): easy tools in the management of chronic respiratory diseases
Year: 2021
Prior cardiovascular disease increases long-term mortality in COPD patients with pneumonia
Source: Eur Respir J 2014; 43: 36-42
Year: 2004
No impact of statins on time to first COPD exacerbation or all-cause mortality
Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data
Year: 2021
Effect of cumulative smoking history on disease burden and multimorbidity in adult-onset asthma
Source: International Congress 2018 – Asthma management
Year: 2018
Desmosine is a predictor of long-term cardiovascular mortality in bronchiectasis
Source: Virtual Congress 2020 – New biomarkers for management of obstructive diseases
Year: 2020
The impact of comorbidities on the short-term serious health outcomes in hospitalized COPD patients due to exacerbation
Source: Annual Congress 2013 –COPD treatment and others
Year: 2013
Under reporting acute exacerbation in patient with COPD: incidence and predictors?
Source: Eur Respir J 2006; 28: Suppl. 50, 175s
Year: 2006
Survival characteristics and predictors of mortality in COPD subjects
Source: International Congress 2019 – Long-term evaluation and control of airway diseases
Year: 2019
Analysis of patients with COPD requiring mechanical ventilation: characteristics, outcomes and risk factors for hospital mortality
Source: Annual Congress 2009 - Intensive care unit management and outcome
Year: 2009
Identification of treatable traits in a severe asthma registry: prevalence and exacerbation predictors
Source: International Congress 2018 – Clinical determinants of asthma and biomarkers
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept